semaglutide cardiovascular indication Population‐level impact of semaglutide 2.4 mg in patients with obesity or Cardiovascular Disease | Ozempic® (semaglutide)
Description
Muayad J, Loya A, Hussain ZS, et al
Semaglutide (s.c.) has shown greater efficacy in reducing body weight as compared to placebo and liraglutide in STEP trials
J., Wildner, A., Gold, A
01375-3/asset/2a0aa5b3-9fde-4bd7-ad14-b865e6ec5eb5/main.assets/gr2_lrg.jpg)
Funding This work was supported by the Ministry of Science and Technology, Taiwan, under grant MOST 109-2320-B-006-047-MY3
The root causes are often economic
It is a GLP-1 receptor agonist that mimics a natural gut hormone, improving blood sugar control, reducing appetite, and supporting weight loss in adults with type 2 diabetes
